Upward Move: Tim Pantello

Tim Pantello
Tim Pantello

Tim Pantello
Managing Director, Digitas Health

Tim Pantello began his career in pharma, like his father, and his father before him. The story changed when he left Sanofi to join one of the first digital agencies, Euro RSCG (now Havas). Today, that detour into marketing has taken him to managing director of a 300-person operation in Philadelphia for Digitas Health.

“I think at the time I felt like I could always go back to the field, but that was 20 years ago,” he says laughing, “I really enjoyed the agency business, the creativity and generation of ideas—so that's where I stayed.”

As global chief creative officer Alexandra Von Plato and president of PHCG Michael du Toit take on additional responsibilities within the Publicis group, Pantello will be left to expand what is already a significant operation.

“One of the goals now is to extend our AOR status to consumer, digital AOR across our current accounts, as well as new clients,” he offers, “We can play across any channel.”

Pantello will do that, in part, by transforming parts of the business model at Digitas to position the firm for other types of clients. Pantello explains that by “further diversifying their business,” they will have an “opportunity to not work with just big pharma, but with smaller biotechs and mid-tier clients.”

Digitas can take advantage of this opportunity because they are “a very different agency,” he points out. “We're a customer-inspired business. From the moment you walk inside, it's a unique environment. The entire setup is very open and collaborative. Everything is designed around freedom of thought. It was designed for the employee, which speaks to the core philosophy of Digitas—that we're built with purpose in mind.”

Pantello attributes his success, in part,  to being patient. “We're in the art of patience,” he says, “Patience creates confidence, decisiveness, and a rational outlook, which leads to ­success.

You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.